Our study showed that 80 out of 95 patients (84.2%) achieved CR after six cycles of R-CHOP therapy, this aligns with findings from prior research that reported CR rates ranging from 60% to 90% in patients with DLBCL treated with R-CHOP [20,21]. The median age of our patients was 46.41 years, which is lower than the median age of 70 years reported in most studies of DLBCL [22]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.